Management of transfusion-dependent β-thalassemia (TDT): Expert insights and practical overview from the Middle East
Amal El‐Beshlawy, Hany Dewedar, Salwa Hindawi, Salam Alkindi, Azza Abdel Gawad Tantawy, Mohamed A. Yassin, Alì Taher
Abstract
β-Thalassemia is one of the most common monogenetic diseases worldwide, with a particularly high prevalence in the Middle East region. As such, we have developed long-standing experience with disease management and devising solutions to address challenges attributed to resource limitations. The region has also participated in the majority of clinical trials and development programs of iron chelators and more novel ineffective erythropoiesis-targeted therapy. In this review, we provide a practical overview of management for patients with transfusion-dependent β-thalassemia, primarily driven by such experiences, with the aim of transferring knowledge to colleagues in other regions facing similar challenges.